Brexit

Roche boss: Brexit will make the UK less competitive

Last week, Roche Boss Severin Schwan expressed concern that Brexit could further slow the UK drug approval process. After the…

NEW Special Report on UK

Despite a myriad of uncertainties around its decision to leave the European Union, the UK still stands as one of…

Brexit Bites: EMA cuts off Britain

The European Medicines Agency has cut Britain out of its contracts 7 months ahead of Brexit. “You might have been…

Brexit: Much ado about nothing?

Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect.…

People to Watch in Brexit

Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of his company. Unlike many of your peers, you are very optimistic about Brexit. What opportunities do you believe Brexit will create for Britain and the life sciences industry in the…

Pfizer’s Nordkamp Takes ABPI Presidency

Erik Nordkamp, managing director of Pfizer UK, has been confirmed as the new president of the Association of the…

Brexit: A Serious Threat to Patients

As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are…

UK Life Sciences Firms Struggle in Post-Brexit War for EU Talent

UK pharmaceutical and biotech companies are already finding it increasingly difficult to attract talent from…

EMA Headquarters to Move to Amsterdam

The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use…

Euratom: Where Are We Now?

Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will &…

Brexit and Irish Pharma

The UK’s decision to leave the EU in Summer 2016 sent shockwaves throughout Europe and left neighbouring…